Peter McWilliams, Glycomine CEO
San Francisco-area biotech gets new cash to launch clinical program for congenital sugar processing disease
A rare disease biotech from the suburbs of San Francisco has returned to the venture well for a Series B extension, aiming to get its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
